161 related articles for article (PubMed ID: 29949671)
1. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis.
Lee KS; Kim BH; Oh HK; Kim DW; Kang SB; Kim H; Shin E
Cancer Sci; 2018 Sep; 109(9):2957-2969. PubMed ID: 29949671
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer.
Oh IH; Pyo JS; Son BK
Curr Oncol; 2021 Aug; 28(4):3139-3149. PubMed ID: 34436040
[TBL] [Abstract][Full Text] [Related]
3. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.
Yang Y; Li CW; Chan LC; Wei Y; Hsu JM; Xia W; Cha JH; Hou J; Hsu JL; Sun L; Hung MC
Cell Res; 2018 Aug; 28(8):862-864. PubMed ID: 29959401
[No Abstract] [Full Text] [Related]
4. Durvalumab for the treatment of non-small cell lung cancer.
Mezquita L; Planchard D
Expert Rev Respir Med; 2018 Aug; 12(8):627-639. PubMed ID: 29958099
[TBL] [Abstract][Full Text] [Related]
5. EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells.
Wang Y; Hu J; Wang Y; Ye W; Zhang X; Ju H; Xu D; Liu L; Ye D; Zhang L; Zhu D; Deng J; Zhang Z; Liu S
Cell Cycle; 2018; 17(12):1457-1470. PubMed ID: 29954240
[TBL] [Abstract][Full Text] [Related]
6. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Vendetti FP; Karukonda P; Clump DA; Teo T; Lalonde R; Nugent K; Ballew M; Kiesel BF; Beumer JH; Sarkar SN; Conrads TP; O'Connor MJ; Ferris RL; Tran PT; Delgoffe GM; Bakkenist CJ
J Clin Invest; 2018 Aug; 128(9):3926-3940. PubMed ID: 29952768
[TBL] [Abstract][Full Text] [Related]
7. PD-L1
Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
[TBL] [Abstract][Full Text] [Related]
8. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.
Battaglin F; Naseem M; Puccini A; Lenz HJ
Cancer Cell Int; 2018; 18():99. PubMed ID: 30008616
[TBL] [Abstract][Full Text] [Related]
9. A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.
Shimada M; Tamura A; Yokosuka K; Kusaka K; Matsui H; Nagai H; Ohta K
Respir Investig; 2018 Jul; 56(4):365-368. PubMed ID: 30008296
[TBL] [Abstract][Full Text] [Related]
10. Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Califano R; Lal R; Lewanski C; Nicolson MC; Ottensmeier CH; Popat S; Hodgson M; Postmus PE
Future Oncol; 2018 Oct; 14(23):2415-2431. PubMed ID: 29978725
[TBL] [Abstract][Full Text] [Related]
11. Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Dupuis F; Lamant L; Gerard E; Torossian N; Chaltiel L; Filleron T; Beylot-Barry M; Dutriaux C; Prey S; Gros A; Jullie ML; Meyer N; Vergier B
Br J Cancer; 2018 Jul; 119(2):193-199. PubMed ID: 29973670
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.
Tay R; Prelaj A; Califano R
J Thorac Dis; 2018 May; 10(Suppl 13):S1494-S1502. PubMed ID: 29951301
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Kulangara K; Zhang N; Corigliano E; Guerrero L; Waldroup S; Jaiswal D; Ms MJ; Shah S; Hanks D; Wang J; Lunceford J; Savage MJ; Juco J; Emancipator K
Arch Pathol Lab Med; 2019 Mar; 143(3):330-337. PubMed ID: 30028179
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
[No Abstract] [Full Text] [Related]
16. Nivolumab Treatment for Cancers in the HIV-infected Population.
Chang E; Sabichi AL; Kramer JR; Hartman C; Royse KE; White DL; Patel NR; Richardson P; Yellapragada SV; Garcia JM; Chiao EY
J Immunother; 2018 Oct; 41(8):379-383. PubMed ID: 30020193
[TBL] [Abstract][Full Text] [Related]
17. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Kim ST; Cristescu R; Bass AJ; Kim KM; Odegaard JI; Kim K; Liu XQ; Sher X; Jung H; Lee M; Lee S; Park SH; Park JO; Park YS; Lim HY; Lee H; Choi M; Talasaz A; Kang PS; Cheng J; Loboda A; Lee J; Kang WK
Nat Med; 2018 Sep; 24(9):1449-1458. PubMed ID: 30013197
[TBL] [Abstract][Full Text] [Related]
20. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
